List of Advanced Rx Recommended For Moderate to Severe UC Expands

The AGA has released an updated guideline on pharmacologic management of adult outpatients with UC that, for the ...

FEBRUARY 4, 2025

New AGA Living Guideline Expands Recommended Drugs for Moderate to Severe UC

The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...

NOVEMBER 26, 2024

Upadacitinib Versus Tofacitinib in UC; Etrasimod for Proctitis

Prospective studies that directly compare the efficacy of two different medications remain rare in our field, ...

NOVEMBER 15, 2024

The ABCs of Optimizing Drug Sequencing for IBD

The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...

OCTOBER 13, 2024

A Miss for FMT in Ulcerative Colitis, Additional Upadacitinib Benefits in Crohn’s

This month’s report looks at two distinct issues: fecal microbiota transplantation and upadacitinib.

SEPTEMBER 17, 2024

Subcutaneous Infliximab or Vedolizumab For Maintenance Therapy in IBD; Fast-Acting Upadacitinib in Crohn’s

In this month’s The Regueiro Report, I highlight two studies on medications to treat inflammatory bowel ...

JUNE 19, 2024

Ultrasound Is Promising for Tighter Control in Patients With Inflammatory Bowel Disease

Point-of-care ultrasound of the abdomen substantially reduces the time to treatment change and time to remission in ...

DECEMBER 28, 2023

Expert Picks From DDW 2023: Crohn’s Disease

In this installment of “Expert Picks” from DDW 2023, Dana Lukin, MD, PhD, discusses six of his ...

JULY 10, 2023

FDA Grants New Indication for Upadacitinib in Crohn’s Disease

The FDA granted a new indication for upadacitinib to treat certain adults with moderate to severe active ...

MAY 19, 2023

Landmark Trials of Risankizumab, Upadacitinib Change Playing Field for Crohn’s Disease, Ulcerative Colitis

This month I am discussing two studies from 2022, highlighting them due to their practice-changing implications.

MARCH 21, 2023

Upadacitinib Benefits UC, Crohn’s Patients As Maintenance Rx

Upadacitinib is effective for maintenance therapy in patients with UC and patients with Crohn's disease, according ...

FEBRUARY 21, 2023

FDA Approves Rinvoq for Treatment of Ulcerative Colitis

The FDA approved upadacitinib (Rinvoq, AbbVie) for the treatment of adults with moderately to severely active ...

MARCH 22, 2022